MedTech Spectrum spoke to Eric Benjamin, Executive Vice President and Chief Product & Customer Experience Officer at Insulet, about the nationwide launch of the Omnipod® 5 iPhone App with Dexcom G7 integration. This milestone combines automated insulin delivery with real-time glucose monitoring—empowering people with diabetes to manage their health more seamlessly and discreetly via smartphone. A major leap toward more personalised, connected care.
What were the key design and clinical priorities behind expanding Omnipod® 5 functionality to the iPhone platform, and how does this improve the user experience for people with diabetes?
Everything we do is tied back to our mission—improving the lives of people with diabetes and enabling our customers to enjoy simplicity, freedom, and healthier lives through our innovative technology. That includes offering full control from a personal Android or iOS smartphone in the U.S. The Omnipod® 5 App for iPhone features an intuitive, iOS-native interface that feels familiar to iPhone users, with real-time glucose data displayed right on the App home screen. Integrating with Dexcom G7 provides more choice for our users with a compatible iPhone.
How does the integration with Dexcom G7 enhance real-time insulin and glucose management compared to previous models, particularly in terms of accuracy, responsiveness, and personalization?
All Omnipod 5 configurations meet our high standards of accuracy and provide an excellent experience for our users. By integrating the Omnipod® 5 App for iPhone with Dexcom G7 we’re enabling more users to manage their diabetes from their preferred device. This enhances convenience and provides more personalization. Additionally, our iPhone users report more engagement with their diabetes management since bringing this innovation to the U.S. market in October 2024 (1)
-
2025 Customer Survey of U.S. adults with Type 1 and Type 2 diabetes, n=654, 89% of Omnipod 5 iOS App users agreed they are more engaged with their diabetes management using their phone
What feedback have you received from early users or pilot programs regarding the transition from a dedicated controller to full app-based control on iOS devices?
Feedback has been overwhelmingly positive since we launched the Omnipod App for iPhone in the U.S. in October 2024. One customer said it best: "It's a big dose of normalcy I didn't know I needed". As users transition from the dedicated Controller to using their iPhone, this reduces the number of devices to manage. The recent integration with Dexcom G7 offers expanded sensor options and greater flexibility, which our users also appreciate.
How is Insulet ensuring data security, seamless updates, and interoperability as more users rely on mobile devices to manage critical aspects of their diabetes care?
Insulet is committed to maintaining the highest standards of data security, with regularly updated policies to reflect the latest best practices. We invest heavily in cybersecurity to ensure that users can safely and securely operate their Omnipod on the mobile device they already carry every day. We also provide seamless over-the-air updates for the Omnipod 5 App, allowing users to easily stay current with the latest software, security protections, and other features available. Additionally, we are continuously expanding our list of compatible devices as new smartphone models and operating systems are released.
With this rollout complete across the U.S., what are the next steps in Insulet’s digital roadmap, particularly around Android support, international expansion, or future CGM integrations?
With this latest integration, we’re expanding access to our phone control platform to our U.S. users making diabetes management more convenient and inclusive. We’ve also recently expanded compatibility to include a wider range of Android devices. In addition, we’re actively working to bring this capability to our international markets and future sensor integrations, offering more choice for people living with diabetes.
